Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Abstract Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Werner Popp, Stefan Lambrecht, Judith Anzures-Cabrera, David Summers, Markus Abt, Annabelle Monnet, Timothy Kilchenmann, Jens Schjodt-Eriksen, Laurent Essioux, Thomas Kustermann, Wagner Zago, Hanno Svoboda, Tania Nikolcheva, Ronald B. Postuma, Gennaro Pagano, Michael Lindemann, PASADENA Investigators, Prasinezumab Study Group
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Digital Medicine
Online Access:https://doi.org/10.1038/s41746-025-01572-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41746-025-01572-8

Similar Items